Alteration of monoaminergic neurotransmission has been implicated in the pathophysiology of mood disorders, and CYP2C9 enzyme activity has been shown to be modulated by serotonin in vitro. The present study was aimed at analysing the frequency of CYP2C9 alleles (*1, *2, *3) among patients suffering from major depressive disorder. In all, 70 such suffering psychiatric outpatients were studied. The CYP2C9 genotypes were determined by allelespecific PCR. The CYP2C9*3 allele frequency was higher (Po0.01) among the patients suffering from major depression than in a population of 89 schizophrenic patients (odds ratio¼3.3) and 138 healthy volunteers (odds ratio¼2.8). The results suggest that CYP2C9 genetic polymorphism may be related to a major depressive disorder due to an alteration in endogenous metabolism, although a linkage between CYP2C9 and some other gene related to depression cannot be ruled out.
INTRODUCTION
Cytochrome P450 (CYP) enzymes are involved in the metabolism of different xenobiotics and several clinically important drugs. Their roles in the metabolism of endogenous substrates, however, are not well understood. CYP enzymes have been described not only in the liver but also in other tissues such as the brain. It is known that CYP2D6 is involved in the metabolism of several psychotropic drugs (haloperidol, thioridazine, risperidone, amitriptyline, imipramine, fluoxetine, etc).
1 CYP2D6 activity has also been related to personality traits (psychic anxiety, psychasthaenia, inhibition of aggression, and socialization), which suggested that CYP2D6 enzyme may have an endogenous neuroactive substrate or product, such as a biogenic neurotransmitter amine. 2 Later, it was reported that this activity might be modulated by certain indoleamines, specifically 5-methoxytryptamine, a serotonin metabolite that has been reported to be a CYP2D6 substrate. 3, 4 CYP2C9 is also involved in the metabolism of several important psychoactive substances (tetrahydrocannabinol, fluoxetine, amitryptyline, phenytoin, etc). 1, 5 It has been reported that CYP2C9 activity is modulated by endogenous substrates such as adrenaline and serotonin. 6 The involvement of CYP2C9 in the metabolism of melatonin has also been suggested. 7 CYP2C9 together with another CYP2C subfamily member, CYP2C8, is located in the 10q24 region. In addition, a linkage between CYP2C9 and CYP2C8 genetic polymorphisms has been reported. 8 This association may be of importance especially for the metabolism of common substrates of CYP2C9 and CYP2C8 enzymes such as arachidonic acid, [9] [10] [11] which has been related to depression.
The present study was aimed at analysing the frequency of CYP2C9 alleles among psychiatric patients suffering from major depression disorder, and among schizophrenic patients and healthy volunteers as control groups.
PATIENTS AND METHODS
In all, 70 white European psychiatric outpatients (23 males and 47 females, mean age: 51714 years) suffering from a major depressive disorder (DSM-IV criteria, APA) and 89 schizophrenic patients (80 males and nine females, mean age: 53714 years), who were attending the Mental Health Centre of Don Benito and the Mérida Psychiatric Hospital (Extremadura, Spain), were studied. All patients were clinically stable, and paying regular visits to the outpatient centres. The depressive patients were being treated with SSRIs (mostly fluoxetine), mianserin, and benzodiazepines. The schizophrenic patients were on antipsychotic drug monotherapy with haloperidol, thioridazine, or risperidone, with some of them concomitantly taking benzodiazepines, anticholinergic, or some other drugs. A group of 138 (69 males and 69 females, mean age: 30711) Spanish healthy volunteers from the same geographical region were also studied for comparisons of CYP2C9 allele frequencies. The study was performed according to the Helsinki Declaration and was approved by the Ethical Committee of the Extremadura University Hospital. After a complete description of the study to the subjects, written informed consent was obtained. The CYP2C9 genotypes were determined by the PCR-RFLP method, as described previously, 13 allowing identification of the allelic variants CYP2C9*1, CYP2C9*2, and CYP2C9*3. Genotype and allele frequencies were compared between the depressed and schizophrenic patients and healthy volunteers by the two-tailed Fisher's test. Hardy-Weinberg equilibrium was determined in each group by comparing the genotype frequencies with the expected values using a contingency table w 2 statistic with Yates's correction. Analysis of the relative risk (odds ratios) was calculated using GraphPad QuickCalcs (GraphPad Software Inc.). P-values less than 0.05 were regarded as statistically significant.
RESULTS
The frequencies of CYP2C9 genotypes of the three groupsmajor depression, schizophrenia, and healthy volunteers (Table 1) 
¼1
.07, df¼5, P¼0.96, respectively). No gender differences were observed in any group (data not shown). The frequency of the CYP2C9*3 allele in patients with major depression was higher (Po0.01) than in the healthy volunteer population or schizophrenic patients (Po0.01) ( Table 1 ). The relative risk (odds ratios) associated with the CYP2C9*1/ *3, *2/*3, and *3/*3 genotypes was 2.73 (95% CI: 1.38-5.39, Po0.01), and with the CYP2C9*3 allele was 2.76 (95% CI: 1.51-5.05, Po0.01) for the depressed group in comparison with the healthy volunteers. The relative risk associated with the CYP2C9*1/*3, *2/*3, and *3/*3 genotypes was 3.14 (95% CI: 1.43-6.90, Po0.01), and with the CYP2C9*3 allele was 3.30 (95% CI: 1.50-6.13, Po0.01) for the depressed group in comparison with the schizophrenic patients.
DISCUSSION
Alteration of monoaminergic neurotransmission has been implicated in the pathophysiology of mood disorders, and current therapeutic drug targets are partly aimed at influencing serotonin in the brain. Since serotonin modulates the activity of the CYP2C9 enzyme, it has been suggested that this enzyme may be involved in the metabolism of serotonin and its metabolites in the brain, and thus influences its turnover. 6 Likewise, the allelic variant CYP2C9*3 of the CYP2C9 gene has been shown to cause decreased enzyme activity (http://www.imm.ki.se/CYPalleles-Nomenclature Committee). Thus, the present results suggest that the high frequency of the CYP2C9*3 allele found among the depressive patients may be linked to the altered serotonin metabolism due to decreased brain activity of the CYP2C9 enzyme. However, the relatively small size of the sample has to be recognized as a potential limitation of the present study. The CYP2C8 and CYP2C9 genes are involved in the metabolism of arachidonic acid, [9] [10] [11] which is related to depression, 12 and a linkage between CYP2C9 and CYP2C8 genetic polymorphisms has been suggested. 8 Therefore, the influence of these or some other genes associated with the pathomechanism of depression cannot be ruled out. 12 The potential clinical relevance of the described association is highlighted by the fact that CYP2C9 is also involved in the metabolism of some antidepressant drugs (in particular, fluoxetine and amitriptyline). 1, 5 Thus, individuals with a CYP2C9*3 allele will have higher than expected plasma concentrations when treated with regular doses of these drugs. In this sense, we have recently shown that CYP2D6*1/*1 patients with CYP2C9*1/*3 genotype have higher fluoxetine plasma concentrations than those with CYP2C9*1/*1.
14 Another relevant clinical consideration for patients carrying the CYP2C9*3 allele is that the decreased metabolic capacity may lead to a higher risk of drug interactions of concomitantly administered CYP2C9 substrates (antidepressants, anticoagulants, antiepileptics, antidiabetics, NSAID drugs, etc). 1, 5 These interactions may increase the risk of such side effects as the upper gastrointestinal bleeding reported during concomitant use of antidepressants and NSAIDs. 15, 16 In conclusion, the present study has shown a higher frequency of CYP2C9*3 allele in major depressive patients compared to schizophrenic patients and healthy volunteers.
